News
SLP
39.70
+0.53%
0.21
Simulations Plus goes ex dividend Monday
Seeking Alpha · 9h ago
Ex-Dividend Reminder: Blackstone, Simulations Plus and ASML Holding
NASDAQ · 1d ago
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
Simulations Plus will attend KeyBanc Capital Markets’ 25th Annual Technology Leadership Forum on August 5, 2024, in Vail, Colorado. Shawn O’Connor, chief executive officer, will join a panel discussion on AI and Digital Solutions for Drug Discovery. Simulations Plus is a leading provider of biosimulation, performance and intelligence solutions for the biopharma industry.
Barchart · 1d ago
Weekly Report: what happened at SLP last week (0715-0719)?
Weekly Report · 4d ago
Simulations Plus Initiated at Market Perform by JMP Securities
Dow Jones · 07/16 09:40
JMP Securities Initiates Coverage On Simulations Plus with Market Perform Rating
Benzinga · 07/16 09:30
Simulations Plus: A Strong Hold Amidst Growth and Strategic Acquisitions
TipRanks · 07/16 04:57
Weekly Report: what happened at SLP last week (0708-0712)?
Weekly Report · 07/15 09:19
Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety
NASDAQ · 07/12 14:07
Simulations Plus Announces New Research Project With The International Collaboration On Cosmetics Safety To Evaluate The Use Of Physiologically-Based Kinetic Modeling Approaches To Advance Animal-Free Science For Cosmetics And Other Non-Pharmaceutical Ingredients
Simulations Plus, Inc. Will evaluate the use of physiologically-based kinetic modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients. The company is a leading provider of simulation to the biopharma industry. Objective to define best practices to support animal- free safety assessment of new chemicals.
Benzinga · 07/11 12:36
Simulations Plus: Steady Growth, But What About The Margins?
Simulations Plus, Inc. Has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. The company is a leading provider of software and consulting services in the drug development market. A $5 stock in 2014, the company is now valued at around 12 times sales.
Seeking Alpha · 07/10 20:59
Weekly Report: what happened at SLP last week (0701-0705)?
Weekly Report · 07/08 09:20
Stock Index Futures Tread Water as Investors Await Key U.S. Jobs Report
U.S. Payrolls reading for June is due later in the day. Minutes of FOMC meeting show officials were ready to raise interest rates if inflation remains elevated. The S&P 500 and Nasdaq 100 ended Wednesday with new record highs. U.S., nonfarm payrolls data will be released in a few hours.
Barchart · 07/05 04:36
Buy Rating Affirmed for Simulations Plus Amidst Strong Growth and Strategic Acquisitions
TipRanks · 07/04 13:15
S&P 500 and Nasdaq 100 Post Record Highs on Fed Rate Cut Hopes
NASDAQ · 07/03 20:42
Simulations Plus Price Target Maintained With a $56.00/Share by Craig-Hallum
Dow Jones · 07/03 17:48
Craig-Hallum Reiterates Buy on Simulations Plus, Maintains $56 Price Target
Benzinga · 07/03 17:38
Sector Update: Health Care Stocks Fall in Afternoon Trading
NASDAQ · 07/03 16:51
BUZZ-U.S. STOCKS ON THE MOVE-Quest Diagnostics, MGM Resorts, Copper miners
U.S. Stock indexes edged higher on Wednesday in a holiday-shortened trading session. The Dow Jones Industrial Average was down 0.13% at 39,281.17. Top three S&P 500 percentage gainers: Tesla, Newmont Corp. Copper miners rise on higher bullion prices. Quest Diagnostics, MGM Resorts, and copper miners rise.
Reuters · 07/03 16:04
Simulations Plus (SLP) Q3 Earnings & Revenues Beat Estimates
NASDAQ · 07/03 14:20
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.